HALO - Halozyme Suffers Pancreatic Cancer Trial Failure Technology Platform Will Keep It Afloat
Halozyme Therapeutics (HALO) announced that its product PEGPH20 failed to achieve statistical significance in a phase 3 study treating patients with metastatic pancreatic cancer. This was a major setback for the company and its shareholders. However, this move prompted it to move quickly to restructure its organization to conserve cash. It still has a lot of promise based on its Enhanze drug delivery technology platform. As long as it still achieves positive developments with its delivery technology, I believe it should still be good in the long term.
Trial Failure Setback
Halozyme announced